Stem Cells Research Development & Therapy
Latest Publications


TOTAL DOCUMENTS

80
(FIVE YEARS 69)

H-INDEX

2
(FIVE YEARS 1)

Published By Herald Scholarly Open Access

2381-2060

2021 ◽  
Vol 7 (4) ◽  
pp. 1-3
Author(s):  
Yehonatan Zur ◽  
◽  
Tzila Davidov ◽  
Limor Baruch ◽  
Marcelle Machluf ◽  
...  

Aiming to restore the normal function of diseased or injured tissues, regenerative therapy approaches are generally based on the engineering of complex tissue-mimicking grafts, encompassing biomaterial scaffolds, stem cells, or their combinations [1-4]. Due to the major role of stem cells in physiological regenerative mechanisms, regenerative therapies normally rely on either stem cells transplantation or stem cell recruitment from the neighboring tissue into the implanted scaffold


2021 ◽  
Vol 7 (4) ◽  
pp. 1-6
Author(s):  
CA González ◽  

Alzheimer’s disease is the most prevalent neurodegenerative disorder in the elderly population. The patients suffer cerebral atrophyas a consequence of extensive neuronal loss, especially in areas that play a role in memory and cognition. Cell therapies approaches have emerged as promising treatments to regenerate the brain tissue of the patients


2021 ◽  
Vol 7 (3) ◽  
pp. 1-7
Author(s):  
Alvaro Yogi ◽  

Tissue engineering has shown great promise in generating vascular grafts with properties similar to that of native blood vessels. Vascular Smooth Muscle Cells (VSMC) are the main component of the vasculature tunica media. Recreation of this layer represents a major challenge in tissue engineering due to difficulties in harvesting and culturing autologous VSMC. The use of stem cells and their inherent ability to differentiate into diverse cell types, including vascular lineages, have been proposed


2021 ◽  
Vol 7 (3) ◽  
pp. 1-4
Author(s):  
Yves Lecarpentier ◽  

Mesenchymal Stem Cells (MSCs) are multipotent stromal cells found in bone marrow and have the capacity to differentiate into myofibroblast. In contractile myofibroblasts, the molecular motor is the non-muscle myosin (NMIIA) which differs from the muscle myosin by its ultra-slow kinetics. The differentiation of MSCs into myofibroblasts is promoted by the “Transforming Growth Factor” (TGF-b) which represents a potentially target against tissue fibrosis and cancer.


2021 ◽  
Vol 7 (3) ◽  
pp. 1-6
Author(s):  
Gabriel Silva Santos ◽  

In this peculiar setting, the infiltrations with BMA proved to be an efficient alternative tool for the treatment of severe thoracic rib trauma and delayed union. The patient returned with no complaints and CT evidence indicated that all of the fractured ribs had complete consolidation. Pain and functional outcome of the chest wall in terms of stability improved with the help of this orthobiologic alternative.


2021 ◽  
Vol 7 (3) ◽  
pp. 1-9
Author(s):  
Pier Paolo Claudio ◽  

This data indicates that the drug cytotoxicity assay aimed at targeting CSCs may be a useful tool for optimizing treatment selection when first-line therapy fails, and when there are multiple clinically-acceptable and -equivalent treatments available.


2021 ◽  
Vol 7 (3) ◽  
pp. 1-7
Author(s):  
Lesley-Ann Martin ◽  

We provide evidence to support the use of TotiCyte as a novel volume reduction technology capable of significantly improving CD34+ stem cell recovery


2021 ◽  
Vol 7 (3) ◽  
pp. 1-4
Author(s):  
Marcos Valadares ◽  

Recently, Biagi et al., 2021 published results of yet another successful demonstration of how hiPSC-derived cardiomyocytes can engraft in rats' hearts and improve their cardiac function [1]. According to the work, these results are probably due to the segmental improvement in areas where the grafts were found


2021 ◽  
Vol 7 (2) ◽  
pp. 1-6
Author(s):  
Maurizio Serafini ◽  

This clinical case report describes and demonstrates how advanced modern implantology can successfully handle severe vertical and horizontal bone defects.


2021 ◽  
Vol 7 (2) ◽  
pp. 1-4
Author(s):  
Angela Maria Trujillo ◽  

The use of haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide (Haplo-PTCy) is increasing in adults, but also in children; this procedure is a good alternative for transplanting pediatric patients lacking a matched family donor; indeed, this is very relevant in regions with economic constraints or with a population which is not well represented in the international donor registries which make access to unrelated cord blood units or bone marrow donors difficult.


Sign in / Sign up

Export Citation Format

Share Document